IDH1 and acute myeloid leukemia: It has been demonstrated that IDH mutant AML cells show enhanced vulnerability to various small molecules of OXPHOS, and the combination of ETC complex I inhibitor: metformin, IACS-010759, and ETC complex III inhibitor ATVQ in combination with an active inhibitor of isocitrate dehydrogenase 1 mutant enzyme (mIDH1 enzyme) impairs mitochondrial activity and increases anti-leukemia efficacy.